(Q47309377)

PubMed publication ID

29241365

13 January 2018

http://europepmc.org/abstract/MED/29241365

review article

1 reference

title

Gabapentin for the treatment of alcohol use disorder (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5957503&resulttype=core&format=json

12 May 2020

0 references

0 references

1 reference

Pharmacology

5 February 2022

determination method or standard

domain-ontology-based fuzzy-powered named-entity recognition matcher

1 reference

General Medicine

5 February 2022

determination method or standard

domain-ontology-based fuzzy-powered named-entity recognition matcher

author name string

Barbara J Mason

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5957503&resulttype=core&format=json

12 May 2020

Susan Quello

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5957503&resulttype=core&format=json

12 May 2020

Farhad Shadan

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5957503&resulttype=core&format=json

12 May 2020

language of work or name

English

0 references

publication date

15 December 2017

1 reference

PubMed publication ID

29241365

13 January 2018

http://europepmc.org/abstract/MED/29241365

published in

Expert Opinion on Investigational Drugs

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5957503&resulttype=core&format=json

12 May 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5957503&resulttype=core&format=json

12 May 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5957503&resulttype=core&format=json

12 May 2020

page(s)

113-124

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5957503&resulttype=core&format=json

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

12 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

A role for brain stress systems in addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Polysomnographic and subjective sleep predictors of alcoholic relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Impaired sleep in alcohol misusers and dependent alcoholics and the impact upon outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Increased REM sleep density at admission predicts relapse by three months in primary alcoholics with a lifetime diagnosis of secondary depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Increased pressure for rapid eye movement sleep at time of hospital admission predicts relapse in nondepressed patients with primary alcoholism at 3-month follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Disulfiram treatment of alcoholism. A Veterans Administration cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

The efficacy of disulfiram for the treatment of alcohol use disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Acamprosate in alcohol dependence: implications of a unique mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Acamprosate produces its anti-relapse effects via calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Does Acamprosate Really Produce its Anti-Relapse Effects via Calcium? No Support from the PREDICT Study in Human Alcoholics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Mining for therapeutic gold

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Comparing Gabapentin with Clonazepam for Residual Sleeping Problems following Antidepressant Therapy in Patients with Major Depressive Disorder: A Randomized Clinical Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Treatment effects of gabapentin for primary insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Effects of gabapentin on sleep in menopausal women with hot flashes as measured by a Pittsburgh Sleep Quality Index factor scoring model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Adjunctive gabapentin in treatment-resistant depression: a retrospective chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

A beneficial effect on mood in partial epilepsy patients treated with gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Importance of gabapentin dose in treatment of opioid withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Gabapentin augmentation therapy in bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Cellular and behavioral interactions of gabapentin with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

The mechanisms of action of gabapentin and pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Acute modulation of calcium currents and synaptic transmission by gabapentinoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Inhibition of neuronal Ca(2+) influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

A summary of mechanistic hypotheses of gabapentin pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

The anticonvulsant gabapentin (neurontin) does not act through gamma-aminobutyric acid-B receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Corticotropin releasing factor-induced amygdala gamma-aminobutyric Acid release plays a key role in alcohol dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Increase in expression of alpha1 and alpha2/delta1 subunits of L-type high voltage-gated calcium channels after sustained ethanol exposure in cerebral cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Transcriptome organization for chronic alcohol abuse in human brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

The acute effects of gabapentin in combination with alcohol in heavy drinkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Gabapentin treatment for insomnia associated with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Gabapentin treatment for alcohol dependence: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Gabapentin combined with naltrexone for the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

The role of gabapentin in the management of alcohol withdrawal and dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Pregabalin is effective against behavioral and electrographic seizures during alcohol withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Efficacy and safety of pregabalin in alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Profiles of pregabalin and gabapentin abuse by postmortem toxicology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Use of Pregabalin - A Nationwide Pharmacoepidemiological Drug Utilization Study with Focus on Abuse Potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Gabapentin does not reduce smoked cocaine self-administration: employment of a novel self-administration procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

A randomized placebo-controlled trial of gabapentin for cocaine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Open-label study of a proprietary treatment program targeting type A gamma-aminobutyric acid receptor dysregulation in methamphetamine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Add-on gabapentin in the treatment of opiate withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Pregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Abuse of Gabapentin is Associated with Opioid Addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Prescription medication misuse among opioid dependent patients seeking inpatient detoxification

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Gabapentin misuse, abuse and diversion: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2018.1417383

Effects of gabapentin on release of gamma-aminobutyric acid from slices of rat neostriatum

21 January 2018

1 reference

12 December 2020

A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma

1 reference

12 December 2020

Replication and extension of Marlatt's taxonomy of relapse precipitants: overview of procedures and results. The Relapse Research Group

1 reference

12 December 2020

Naltrexone and alcohol dependence. Role of subject compliance

1 reference

12 December 2020

Effect of anticonvulsants on nocturnal sleep in epilepsy

1 reference

12 December 2020

Importance of sleep restoration in co-morbid disease: effect of anticonvulsants.

1 reference

12 December 2020

Gabapentin in the treatment of cocaine dependence: a case series.

1 reference

12 December 2020

The anticonvulsant, antihyperalgesic agent gabapentin is an agonist at brain gamma-aminobutyric acid type B receptors negatively coupled to voltage-dependent calcium channels

1 reference

12 December 2020

Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy

1 reference

12 December 2020

Gabapentin in the management of pentazocine dependence: a potent analgesic--anticraving agent

1 reference

12 December 2020

Gabapentin reduces cocaine use among addicts from a community clinic sample

1 reference

12 December 2020

A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm

1 reference

12 December 2020

Gabapentin improves sleep in the presence of alcohol.

1 reference

12 December 2020

Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled, multicenter, 28-day, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance

1 reference

12 December 2020

Trial of tramadol plus gabapentin for opioid detoxification.

1 reference

12 December 2020

Prescription medication misuse among opioid dependent patients seeking inpatient detoxification

1 reference

12 December 2020

10.1080/13543784.2018.1417383

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5957503&resulttype=core&format=json

12 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5957503&resulttype=core&format=json

12 May 2020

PubMed publication ID

29241365

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC5957503&resulttype=core&format=json